HK1165547A1 - Use of endostatin as a marker of heart failure - Google Patents

Use of endostatin as a marker of heart failure

Info

Publication number
HK1165547A1
HK1165547A1 HK12105510.6A HK12105510A HK1165547A1 HK 1165547 A1 HK1165547 A1 HK 1165547A1 HK 12105510 A HK12105510 A HK 12105510A HK 1165547 A1 HK1165547 A1 HK 1165547A1
Authority
HK
Hong Kong
Prior art keywords
endostatin
marker
heart failure
heart
failure
Prior art date
Application number
HK12105510.6A
Other languages
English (en)
Chinese (zh)
Inventor
Ursula-Henrike Wienhues-Thelen
Dirk Block
Hendrik Huedig
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1165547A1 publication Critical patent/HK1165547A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/515Angiogenesic factors; Angiogenin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK12105510.6A 2009-04-27 2012-06-06 Use of endostatin as a marker of heart failure HK1165547A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09005801 2009-04-27
PCT/EP2010/002513 WO2010124821A1 (en) 2009-04-27 2010-04-23 Use of endostatin as a marker of heart failure

Publications (1)

Publication Number Publication Date
HK1165547A1 true HK1165547A1 (en) 2012-10-05

Family

ID=41134573

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105510.6A HK1165547A1 (en) 2009-04-27 2012-06-06 Use of endostatin as a marker of heart failure

Country Status (8)

Country Link
US (1) US20120009610A1 (xx)
EP (1) EP2425245B1 (xx)
JP (1) JP2012524282A (xx)
CN (1) CN102422157B (xx)
CA (1) CA2756120C (xx)
ES (1) ES2607491T3 (xx)
HK (1) HK1165547A1 (xx)
WO (1) WO2010124821A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021026652B1 (pt) 2011-10-17 2022-08-23 F. Hoffmann-La Roche Ag Método in vitro para diagnosticar fibrilação atrial intermitente, uso de uma troponina cardíaca e dispositivo para diagnosticar fibrilação atrial intermitente
EP2895866B1 (en) * 2012-09-12 2018-05-30 Roche Diagnostics GmbH Identification of patients with abnormal fractional shortening
EP2929354B1 (en) 2012-12-04 2018-04-18 Roche Diagnostics GmbH Biomarkers in the selection of therapy of heart failure
EP2843414B1 (en) * 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
ES2939018T3 (es) 2014-03-26 2023-04-18 Hoffmann La Roche IGFBP7 para diagnosticar una disfunción diastólica
EP3213085B2 (en) * 2014-10-29 2022-09-28 Roche Diagnostics GmbH Biomarkers for risk prediction of progression of chronic heart failure and mortality
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
GB201912856D0 (en) * 2019-09-06 2019-10-23 Nordic Bioscience As Assay for assessing heart failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743031A4 (en) * 2004-04-26 2008-05-28 Childrens Medical Center BLOOD PLATE BIOMARKERS FOR THE DETECTION OF ILLNESSES
EP1967853B1 (en) * 2007-03-06 2010-01-27 Roche Diagnostics GmbH Use of Nogo-C in the assessment of heart failure
JP5045906B2 (ja) * 2007-06-26 2012-10-10 国立大学法人山口大学 新規虚血マーカー及びこれを用いた虚血状態の検出方法
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法

Also Published As

Publication number Publication date
ES2607491T3 (es) 2017-03-31
JP2012524282A (ja) 2012-10-11
EP2425245B1 (en) 2016-10-05
CN102422157B (zh) 2014-10-29
CA2756120C (en) 2022-08-30
US20120009610A1 (en) 2012-01-12
EP2425245A1 (en) 2012-03-07
WO2010124821A1 (en) 2010-11-04
CA2756120A1 (en) 2010-11-04
CN102422157A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
HK1165547A1 (en) Use of endostatin as a marker of heart failure
EP2393914A4 (en) LUNG TISSUE ENGINEERING
PL2480218T3 (pl) Kapsułki odporne na kwas
EP2408400A4 (en) RECONFIGURATION OF CARDIAC CHARACTERISTICS
IL222888A0 (en) Anchored cardiac ablation catheter
EP2391979A4 (en) TRACKING OF FABRICS
EP2506888A4 (en) Total artificial heart
GB0907874D0 (en) Skin marker
EP2502068A4 (en) URINARY TRIAOSYLCERAMIDE (GB3) AS A MARKER OF CARDIAC DISEASE
HK1166130A1 (en) Use of s-erbb-3 as a marker for cancer s-erbb-3
EP2478927A4 (en) CATHETER
PL2506733T3 (pl) Podeszwa
GB0907222D0 (en) Pressure joint
EP2448627A4 (en) SAFETY CATHETER
HK1167092A1 (en) Modified agrin-fragment capable of restoring muscle strength for use as a medicament
GB2475743B (en) Balloon catheter
GB0908071D0 (en) Marker
HK1169314A1 (zh) δ-生育酚-碳水化合物作為脫色劑的用途
HK1165204A1 (en) Cybp as a marker of lung cancer cybp
GB0921060D0 (en) Catheter
GB0905964D0 (en) Marker
ZA201106839B (en) A heart valve
IL218326A0 (en) Use of cathepsin h
EP2467494A4 (en) PON1 AS A MARKER FOR HEART FAILURE
GB0917974D0 (en) A walking staff